Cargando…

Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T‐cell lymphoma

Pralatrexate is a novel antifolate approved in the USA for the treatment of relapsed or refractory peripheral T‐cell lymphoma. To assess its safety, efficacy, and pharmacokinetics in Japanese patients with this disease, we undertook a phase I/II study. Pralatrexate was given i.v. weekly for 6 weeks...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maruyama, Dai, Nagai, Hirokazu, Maeda, Yoshinobu, Nakane, Takahiko, Shimoyama, Tatsu, Nakazato, Tomonori, Sakai, Rika, Ishikawa, Takayuki, Izutsu, Koji, Ueda, Ryuzo, Tobinai, Kensei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623731/ https://www.ncbi.nlm.nih.gov/pubmed/28771889 http://dx.doi.org/10.1111/cas.13340

Ejemplares similares

Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review
por: Makita, Shinichi, et al.
Publicado: (2018)

Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell Lymphoma
por: Rodd, Annabelle L., et al.
Publicado: (2012)

Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2016)

Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2018)

Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
por: Lee, Seung-Shin, et al.
Publicado: (2016)

Relapsed refractory nodal peripheral T-cell lymphoma with follicular helper T-cell phenotype was initially resistant to pralatrexate and confirmed to be unresponsive to subsequent forodesine, but responded to re-instituted pralatrexate
por: Sekiguchi, Yasunobu, et al.
Publicado: (2020)

Novel Interleukin‐2 Dependent T‐Cell Line Derived from Adult T‐Cell Leukemia Not Associated with Human T‐Cell Leukemia Virus Type I
por: Kagami, Yoshitoyo, et al.
Publicado: (1993)

Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma
por: Negoro, Eiju, et al.
Publicado: (2023)

Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study
por: Izutsu, Koji, et al.
Publicado: (2021)

Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma
por: Munakata, Wataru, et al.
Publicado: (2021)

Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study
por: Hong, Xiaonan, et al.
Publicado: (2019)

Pralatrexate for refractory mycosis fungoides in two Japanese patients
por: Teraishi, Mika, et al.
Publicado: (2021)

Promising results of an anti-CCR4 antibody, KW-0761, for relapsed Adult T-Cell Leukemia-Lymphoma (ATL)
por: Utsunomiya, Atae, et al.
Publicado: (2011)

Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin
por: Kitazume, Koichi, et al.
Publicado: (2019)

Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study
por: Iida, Shinsuke, et al.
Publicado: (2019)

Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial
por: Maruyama, Dai, et al.
Publicado: (2018)

A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
por: Watanabe, Takashi, et al.
Publicado: (2016)

Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2019)

Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors
por: Suzuki, Tomotaka, et al.
Publicado: (2020)

Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment
por: Merdin, Alparslan, et al.
Publicado: (2019)

E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T‐cell lymphoma: A phase I study
por: Ohmachi, Ken, et al.
Publicado: (2018)

Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study
por: Kim, Won-Seog, et al.
Publicado: (2023)

Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea
por: Ogura, Michinori, et al.
Publicado: (2020)

Safety and effectiveness of mogamulizumab in relapsed or refractory adult T‐cell leukemia‐lymphoma
por: Ishitsuka, Kenji, et al.
Publicado: (2019)

Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment: Erratum
Publicado: (2020)

Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
por: Maruyama, Dai, et al.
Publicado: (2020)

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018)

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
por: Izutsu, Koji, et al.
Publicado: (2023)

Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study
por: Ohmachi, Ken, et al.
Publicado: (2018)

Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis
por: Hong, Jung Yong, et al.
Publicado: (2019)

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity
por: Serova, M, et al.
Publicado: (2011)

Antiviral Efficacy of Pralatrexate against SARS-CoV-2
por: Bae, Joon-Yong, et al.
Publicado: (2021)

Genetic Alteration of p53 in Some Patients with Adult T‐Cell Leukemia
por: Nagai, Hirokazu, et al.
Publicado: (1991)

An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma
por: Izutsu, Koji, et al.
Publicado: (2023)

Mogamulizumab for relapsed adult T‐cell leukemia–lymphoma: Updated follow‐up analysis of phase I and II studies
por: Ishida, Takashi, et al.
Publicado: (2017)

Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma
por: Casanova, M, et al.
Publicado: (2011)

Radiation Recall Dermatitis After the Use of Pralatrexate for Peripheral T-cell Lymphoma
por: Bhangoo, Ronik S., et al.
Publicado: (2018)

Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance
por: Oiwa, Kana, et al.
Publicado: (2021)

Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T‐cell lymphoma
por: Kawai, Hidetsugu, et al.
Publicado: (2021)

Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma
por: Makita, Shinichi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tcfqpfatk03cokeehs9s50lkrt